Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma

Authors

James R. Berenson, James R. Berenson, MD, Inc., Los Angeles, CA
Ori Yellin, James R. Berenson, MD, Inc., Los Angeles, CA
Alberto Bessudo, San Diego Pacific Oncology Hematology Associates, Inc., Encinitas, CA
Ralph V. Boccia, Center for Cancer and Blood Disorders, Bethesda, MD
Stephen J. Noga, Franklin Square Hospital, Baltimore, MD
Donald S. Gravenor, Family Cancer Center Foundation, Memphis, TN
Dipti Patel-Donnelly, Virginia Cancer Specialists, PC, Fairfax, VA
Robert S. Siegel, George Washington UniversityFollow
Tarun Kewalramani, Geisinger Medical Center, Danville, PA
Edward J. Gorak, Lahey Clinic, Burlington, MA
Youram Nassir, Cancer Care Institute, Los Angeles, CA
Regina A. Swift, James R. Berenson, MD, Inc., Los Angeles, CA
Debra Mayo, Teva Pharmaceutical Industries Ltd., Frazer, PA

Document Type

Journal Article

Publication Date

2-2013

Journal

British Journal of Haematology

Volume

Volume 160, Issue 3

Inclusive Pages

321-330

Keywords

Antineoplastic Combined Chemotherapy Protocols--therapeutic use; Multiple Myeloma--drug therapy

APA Citation

Berenson, J. R., Yellin, O., Bessudo, A., Boccia, R. V., Noga, S. J., Gravenor, D. S., Patel-Donnelly, D., Siegel, R.S., Kewalramani, T., Gorak, E.J., Nassir, Y.l, Swift, R.A., Mayo, D. (2013). Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. British Journal of Haematology, 160(3), 321-330.

Peer Reviewed

1